Immediate Impact
48 standout
Citing Papers
MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future
2024 Standout
Bispecific antibodies: advancing precision oncology
2024 Standout
Works of Matteo Duca being referenced
Targeted protein degraders from an oncologist point of view: The Holy Grail of cancer therapy?
2021
EGFR tyrosine kinase inhibitors beyond focal progression obtain a prolonged disease control in patients with advanced adenocarcinoma of the lung
2013
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Matteo Duca | 77 | 38 | 53 | 18 | 130 | |
| Katherine V. Ferry‐Galow | 93 | 36 | 51 | 23 | 161 | |
| Alexandre Wicky | 88 | 32 | 39 | 15 | 148 | |
| Dhanusha Sabanathan | 96 | 25 | 64 | 23 | 143 | |
| Hanmei Lou | 85 | 18 | 21 | 11 | 133 | |
| Anne Sibille | 132 | 50 | 79 | 21 | 194 | |
| Mohammad Atiq | 88 | 53 | 62 | 20 | 149 | |
| Azam Ghafoor | 80 | 55 | 78 | 15 | 198 | |
| Julia Dudnik | 82 | 31 | 85 | 23 | 137 | |
| Lu Pei | 70 | 113 | 49 | 17 | 209 | |
| Robert P. Whitehead | 113 | 33 | 34 | 11 | 177 |
All Works
Login with ORCID to disown or claim papers
Loading papers...